Liver disease biotech Genfit sets terms for $132 million US IPO

Shutterstock photo

Genfit, a Phase 3 biotech developing therapies for NASH, announced terms for its US IPO on Thursday.

The Loos, France-based company plans to raise $132 million in a global offering of 5.0 million shares at $26.33, the as-converted last close of its shares on the Euronext Paris. At that price, Genfit would command a fully diluted market value of $955 million. The global offering also includes a European private placement of an undisclosed size.

Genfit's lead candidate elafibranor is being studied in a Phase 3 clinical trial for liver disease nonalcoholic steatohepatitis (NASH). 

Genfit was founded in 1999 and booked $8 million in grant and other revenue for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol GNFT. SVB Leerink and Barclays are the joint bookrunners on the deal. It is expected to price later this month.

The article Liver disease biotech Genfit sets terms for $132 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?